{
    "id": 15203,
    "fullName": "ERC1 - RET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERC1-RET (also referred to as ELKS-RET) results from the fusion of ERC1 and RET, and leads to constitutive tyrosine phosphorylation in cultured cells (PMID: 12203787). ERC1-RET fusions have been identified in papillary thyroid carcinoma (PMID: 12203787, PMID: 10697956).",
            "references": [
                {
                    "id": 11210,
                    "pubMedId": 10697956,
                    "title": "Genomic organization and chromosomal mapping of ELKS, a gene rearranged in a papillary thyroid carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10697956"
                },
                {
                    "id": 4107,
                    "pubMedId": 12203787,
                    "title": "Differential expression of multiple isoforms of the ELKS mRNAs involved in a papillary thyroid carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12203787"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 23085,
        "geneSymbol": "ERC1",
        "terms": [
            "ERC1",
            "Cast2",
            "ELKS",
            "ERC-1",
            "RAB6IP2"
        ]
    },
    "variant": "ERC1 - RET",
    "createDate": "12/13/2015",
    "updateDate": "04/12/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 21073,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with lung adenocarcinoma harboring ERC1-RET did not response to Cometriq (cabozantinib) treatment (PMID: 27825636; NCT01639508).",
            "molecularProfile": {
                "id": 15466,
                "profileName": "ERC1 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7513,
                    "pubMedId": 27825636,
                    "title": "Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27825636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15466,
            "profileName": "ERC1 - RET",
            "profileTreatmentApproaches": [
                {
                    "id": 17903,
                    "name": "RET Inhibitor",
                    "profileName": "ERC1 - RET"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}